Alexey Rak
Alexey Rak has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Aiqun Li
Sanofi 8 DMPK Cambridge, Massachusetts
24 shared publications - Alyssa La Belle Flynn
Sanofi 2 Oncology Research Cambridge, Massachusetts
24 shared publications - Ana Paula B. Vintém
Sanofi 1 NANOBODY Research Platform Ghent, Belgium
24 shared publications - Ann Baker
Sanofi 9 Preclinical Safety Cambridge, Massachusetts
24 shared publications - Eduardo M. Bruch
Institut Pasteur
24 shared publications - Ernesto Luna
Sanofi 7 Vaccine Research and Development Orlando, Florida
24 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S8 is a heatmap of cytokine concentration as measured using Luminex multiplex array after MIMIC CRA for comparison of TPP-45142 and TPP45131
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S8 is a heatmap of cytokine concentration as measured using Luminex multiplex array after MIMIC CRA for comparison of TPP-45142 and TPP45131
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S9 comprises of statistical results for comparison of all groups with the vehicle group (daily)
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S9 comprises of statistical results for comparison of all groups with the vehicle group (daily)
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S7 compares statistical results for tumor accumulation of TPP-45142 and TPP-45161 at each time point
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S7 compares statistical results for tumor accumulation of TPP-45142 and TPP-45161 at each time point
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S4 shows that TPP-45142 did not induce HER2-low breast cancer cell proliferation. ZR-75-1 proliferation in the presence of TPP-45142. EGF was used as positive control and TPP-45161 as non-HER2 negative control (Neg. Ctrl), as measured by confluence using IncuCyte
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S4 shows that TPP-45142 did not induce HER2-low breast cancer cell proliferation. ZR-75-1 proliferation in the presence of TPP-45142. EGF was used as positive control and TPP-45161 as non-HER2 negative control (Neg. Ctrl), as measured by confluence using IncuCyte
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S3 represents binding parameters of TPP-45142 with individual HER2-binding NANOBODY domains (human and cynomolgus HER2) and with TCRab-binding NANOBODY domain (human and cynomolgus TCRαβ zipper)
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S3 represents binding parameters of TPP-45142 with individual HER2-binding NANOBODY domains (human and cynomolgus HER2) and with TCRab-binding NANOBODY domain (human and cynomolgus TCRαβ zipper)
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S6 shows PK parameters calculated from the exposure of the 89Zr-labeled NANOBODY molecules in blood samples of ZR-75-1 tumor-bearing NSG mice engrafted with in vitro expanded T cells
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S6 shows PK parameters calculated from the exposure of the 89Zr-labeled NANOBODY molecules in blood samples of ZR-75-1 tumor-bearing NSG mice engrafted with in vitro expanded T cells
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S5 shows that there was no adverse uptake for TPP-45142 compared with TPP-45161 in different organs. Heart, liver, kidney and spleen accumulation of 89Zr-TPP-45142 or non-HER2 negative control 89Zr-TPP-45161 as measured by PET/CT imaging (n = 3) (time: post radiolabeled-compound injection).
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S5 shows that there was no adverse uptake for TPP-45142 compared with TPP-45161 in different organs. Heart, liver, kidney and spleen accumulation of 89Zr-TPP-45142 or non-HER2 negative control 89Zr-TPP-45161 as measured by PET/CT imaging (n = 3) (time: post radiolabeled-compound injection).
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S11 shows in vitro cytotoxicity of TPP-45131 and TPP-45142 in breast cancer cell lines and primary cells
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S11 shows in vitro cytotoxicity of TPP-45131 and TPP-45142 in breast cancer cell lines and primary cells
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S8 shows ΔT/ΔC values on day 36
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Table S8 shows ΔT/ΔC values on day 36
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S6 shows that EA. hy926 cells were cultured to confluency, harvested, and stained using anti-HER2-FITC antibody. Histograms depict HER2 expression profile. Blue histogram represents unstained control, and red histogram represents HER2 FITC-stained cells. This is a representative example of two experiments.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Supplementary Figure S6 shows that EA. hy926 cells were cultured to confluency, harvested, and stained using anti-HER2-FITC antibody. Histograms depict HER2 expression profile. Blue histogram represents unstained control, and red histogram represents HER2 FITC-stained cells. This is a representative example of two experiments.